7 Literaturverzeichnis

[11] Morrow C, .Paul MD, Cozen W (1995). Perspective on cervical cancer: Why prevent? J of Cell Biochem 23 Suppl. : 61-70
[2] Sherman, M E. ., Kurman, RJ(1998). Intraepithelial carcinoma of the cervix: Reflections on half a Century of Progress. Cancer 83: 2243-2246
[3] Henry M. The Bethesda System, the Pathology of Preinvasive Lesions, and Screening Technology (1996). J of the NCI Monographs 26: 13-16
[4] Benedet J, Odicino F, Severi G et al (1998). Carcinoma of the cervix uteri. In: FIGO Annual Report on the results of treatment in gynaecological cancer. J of Epidem and Biostat 3(1): 5-34
[5] Munoz N, Bosch X, de Sanjose S et al(2003). Epidemiologic Classification of Human Papillomavirus Types associated with cervical cancer. NEJM 348(6):518-527
[6] Walboomers JM, Jacobs MV, Manos MM et al. (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189: 12-19
[7] Kessler II (1976). Human cervical cancer as a veneral disease. Cancer Res 36: 783-791
[8] Rotkin ID (1967). Epidemiology of cancer of the cervix.3. Sexual characterictics of a cervical cancer population. Am J Public Health Nations Health 57: 815-829
[9] Schneider A, Dürst M, Kaufmann AM (2001). HPV-Infektion und Zervixkarzinom – Epidemiologie, Nachweis und Immunologie . Zentralbl Gynekol 123: 179-185
[10] Koutsky LA, Ault KA, Wheeler CM et al (2002). A controlled trial of a human papillomavirus type 16 vaccine. NEJM 347 (21): 1645-1651.
[11] Winkelstein W Jr (1990). Smoking and cervical cancer-current status:a review. Am J Epidemiol 131: 945-957
[12] Schneider V, Kay S, Lee HM (1983). Immunosuppression as a high-risk factor in the development of condyloma acuminatum and squamous neoplasia of the cervix. Acta Cytol 27: 220-224
[13] Halpert R, Fruchter RG, Sedlis A et al (1986). Human Papillomavirus infection and lower genital neoplasia in renal transplant patients. Obstetrics Gynecol 68: 251-258
[14] Magnusson PK, Sparen P, Gyllensten UB (1999). Genetic linkage to cervical tumours . Nature 400:29-30
[15] Mitchell MF, Tortolero-Luna G, Wright T et al (1996). Cervical Human Papillomavirus Infection and Intraepithelial Neoplasia: a review. J of the NCI Monographs 21: 17-25
[16] Östör AG (1993). Natural history of cervical intraepithelial neoplasia: a critical review . Int J Gynecol Pathol 12:186-192
[17] Cramer DW, Cutler SJ(1974). Incidence and histopathology of malignancies of the femal genital organs in the United States. Am J Obstetrics Gyecol 118: 443-460
[18] Herrero R (1996). Epidemiology of Cervical Cancer. J of the NCI Monographs 21: 1-6
[19] Elliott PM, Tattersall MHN, Coppleson M et al (1989). Changing character of cervical cancer in young women. Br J Med 298: 288-290
[20] Sreekantai C, Bhargava MK, Shetty NJ (1988). Chromosome 1 alterations in cervical carcinoma. Cancer 62: 1317-1324
[21] Segers P, Haesen S, Amy JJ et al (1994). Detection of premalignant stages in cervical smears with a biotiylated probe for chromosome 1. Cancer Genet. Cytogenet. 75: 120-129
[22] Chung GT, Huang DP, Lo KW et al. (1992). Genetic lesions in the carcinogenesis of cervical cancer. Anticancer Res. 12: 1485-1490
[23] Hampton GM, Penny LA, Baergen RN et al.(1991). Loss of Heterozygosity in cervical carcinoma: subchromosomal localization of a putative tumor-suppressor gene to chromosome 11q22-q24. Proc. Natl. Acad. Sci. USA: 6953-6957.
[24] Atkin NB, Baker MC, Fox MF (1990). Chromosome changes in 43 carcinomas of the cervix uteri. Cancer Genet. Cytogenet. 44: 229-241
[25] Kamura T, Tsukamoto N, Tsuruchi N et al (1992). Multivariate Analysis of the histopathologic Prognostic Factors of Cervical Cancer in Patients undergoing Radical Hysterektomie. Cancer 69(1):S.181-186
[26] Hale RJ, Wilcox FL, Buckley CH et al (1991). Prognostic factors in uterine cervix carcinoma: a clinicopathologica analysis. Int. J Gynecol Cancer 1: 19-23
[27] Toshiharu K , Tsukamoto N, Tsuruchi N et al (1992). Multivariate Analysis of the histopathologic prognosis factors of cervical cancer in Patients undergoing radical hysterectomy. Cancer Vol.69, No. 1 S.181-186
[28] Pickel H, Haas J, Lahousen M. (1997): Prognstic factors in cervical cancer. Eur J Obstet Gynecol Reprod Biol 71: 209-213

[29] Palefski JM, Holly EA (1995).Molecular virology and epidemiology of human papillomavirus and cervical cancer. Cancer Epidemiol Biomarkers Prev 4:415-28
[30] Maiman M, Fruchter RG, Guy L et al (1993). Human deficiency virus infection and invasive cervical carcinoma. Cancer 71: 402-406
[31] Macleod A, Kitchener HC, Parkin DE et al.(1994). Cervical carcinoma in the Grampian region (1980-1991) : a population-based study of survival and clinical cytology history. Br J Obstet. Gynecol 101:797-803
[32] Bourhis J, Le MG, Barrois M et al (1990). Pognostic value of c-myc proto-oncogene overexpression in early invasive carcinoma of the cervix. Journal of Clin Oncol 8: 1789-1796.
[33] Strang P, Eklund G, Stendahl B et al (1987). S-phase rate as a predictor of early recurrences in carcinoma of the uterine cervix. Anticancer Res 7 (4B): 807-810 .
[34] Brown DC, Cole DJ, Gatter KC et al (1988). Carcinoma of the Cervix: An assessment of tumour proliferation using the monoklonal antibody Ki-67. Br J of Cancer 57:178-181
[35] Riou G, Barrois M, Sheng ZM et al (1988). Somatic deletions and mutations of c-Ha-ras genen in human cervical cancers. Oncogene 3: 329-333
[36] Hayashi Y, Hachisuga T, Iwasaka T et al (1991). Expression of ras oncogene product and EGF receptor in cervical squamous cell Karzinomas and its relationship to lymph node involvement. Gynecol. Oncol. 40: 147-151
[37] Sagae S, Kuzumaki N, Hisada T et al (1989). ras oncogene expression and prognosis of invasive squamous cell carcinomas of the uterine cervix. Cancer 63: 1577-1582
[38] Holm R, Skomedal H, Helland A et al (1993). Immunhistochemical analysis of p53 protein overexpression in normal, premalignant and malignant tissues of the cervix uteri. J Pathol 169: 21-26
[39] Benjamin I, Saigo P., Finstad C et al (1996). Expression and mutational analysis of p53 in stage IB and IIA cervical cancers. Am J Obstet Gynecol 175 : 1266-1271
[40] Inoue T, Fujita M, Enomoto T et al (1994). Immunhistochemical analysis of p 53 in gynecologic tumors. Am J Clin Pathol 102 : 665-670
[41] Kainz C, Kohlberger P, Gitsch G et al (1995). Mutant p53 in patients with invasive cervical cancer stages IB to IIB. Gynecol. Oncol. 57: 212-214
[42] Avall Lundquist EH, Silfversward C, Aspenblad U et al (1997). The impact of tumour angiogenesis, p53 overexpression and proliferative activity (MIB-1) on survival in squamous cervical Karzinoma. Eur J Cancer 33: 1799-1804
[43] Uchiyama M, Iwasaka T, Matsuo N et al (1997). Correlation between human papillomavirus positivity and p 53 gene overexpression in adenocarcinoma of the uterine cervix. Gynecol Onc 65:23-29
[44] van Driel WJ, Tjiong MY, Hilders CG et al (1996). Association of allele-specific HLA expression and histopathologic progression of cervical carcinoma. Gynecol. Oncol 62: 33-41
[45] Rani S, Vaidya MC, Rani K (1992). Role of cell growth factor (interleukin 2) and its receptor in cervix carcinoma patients. J Steroid Biochem. Mol. Biol. 41:837-839
[46] Tangir J, Loughridge NS, Berkowitz RS et al (1996). Frequent mikrosatellite instability in epithelial borderline ovarian tumors. Cancer Res. 56:2501-2505
[47] Duk JM, Groenier KH, De Bruijn HW et al (1996). Pretreatment serum squamous cell carcinoma antigen: a newly identified prognostic factor in early-stage cervical carcinoma. J Clin Oncol 14: 111-118
[48] Kjorstad KE, Kolbenstvedt A, Strickert T (1984). The value of complete lymphadenektomy in radical treatment of cancer of the cervix, Stage IB. Cancer 54: 2215-2219
[49] Leminen A (1990). Tumor markers CA 125, carcinoembryonic antigen and tumor-associated trypsin inhibitor in patients with cervical adenocarcinoma. Gynecol. Oncol. 39: 358-363
[50] Burger RA, Monk BJ, Kurosaki T et al. (1996). Human papillomavirus type 18: association with poor prognosis in early stage cervical cancer. J Natl. Cancer Inst. 88: 1361-1368
[51] Lombard I, Vincent-Salomon A, Validire P et al (1998). Human papillomavirus genotype as a major determinant of the course of cervical cancer. J Clin. Oncol 16: 2613-2619
[52] Nakagawa S, Yoshikawa H, Onda T et al (1996). Type of human papillomavirus is related to clinical features of cervical carcinoma. Cancer 78: 1935-1941
[53] Sastry SK, Horwitz AF (1996). Adhesion Growth Factor Interactions during Differentiation: An Integrated Biological Response. Develop Biol 180:455-467
[54] Southern SA, Herrington CS (1998). Molecular events in uterine cervical cancer. Review. Sex Transm Inf 74: 101-109
[55] Salomon DS, Brandt R, Ciardello F et al. (1995). Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol hematol 19: 183-232
[56] Turner MA, Darragh T, Palefsky JM (1997). Epithelial-Stromal Interactions Modulating Penetration of Matrigel Membranes by HPV 16-Immortalized Keratinozytes. J of Inv Dermatol 109: 619-625

[57] Wilding J, Vousden KH, Soutter WP et al (1996): E-Cadherin Transfection Down Regulates the Epidermal Growth Factor Receptor and Reverses the Invasive Phenotype of Human Papilloma Virus –transfected Keratinocytes. Cancer Res 56: 5285-5292
[58] Nuovo GJ (1997): In Situ Detection of PCR-Amplified Metalloproteinase cDNAs, their Inhibitors and Human Papillovirus Transcripts in Cervical Karzinoma Cell Lines. Int J Cancer 71: 1056-1060
[59] Ueda M, Ueki M, Terai Y et al (1997). Stimulatory effects of EGF and TGF alpha on invasive activity and 5'Desoxyfluorouridine sensitivity in uterine cervical Karzinoma SKG III B cells. Int J Cancer 72: 1027-1033
[60] Price JT, Wilson HM, Haites NE (1996). Epidermal Growth Factor (EGF) Increases In Vitro Invasion, Motility and Adhesion Interactions of the Primary Renal Karzinoma Cell Line A704. Eur J Cancer 32A:1977-1982
[61] Jiang D, Liang L, Humphrey L et al (1998). Expression of TGF alpha autocrine activity in human colon carcinoma CBS cells is autoregulated and Independent of exogenous epidermal growth factor. J Cell Physiol 175:174-183
[62] Etessami A, Bourhis J (2000). Cetuximab. Drugs of the future 25(9):895-899
[63] Noonberg SB, Benz CC (2000). Tyrosine kinase inhibitors targeted to the Epidermal Growth Factor Receptor Subfamily. Drugs 59(4): 753-767
[64] Salomon DS, Bianco C, De Santis M et al. Epidermal Growth factor-related peptides in endocrine neoplasias. Contemporary Endocrinology: Endocrine Oncology 9:137-191
[65] Adamson ED, Minchiotti G, Salomon DS (2002). Cripto: A Tumor Growth Factor and More. J of Cell Physiol 190:267-278
[66] Ciccodicola A, Dono R, Obici S et al (1989). Molecular Characterisation of a gene of the "EGF family" expressed in undifferentiated human NTERA2 teratoKarzinoma cells.EMBO J 8: 1987-191
[67] Salomon DS, Bianco C, De Santis M (1999). CR-1:a novel epidermal growth factor (EGF)-related peptide in mammary gland development and neoplasia. Bio Essays 21.1: 61-70
[68] Bianco C, Wechselberger C, Ebert A et al (2001). Identification of CR-1 in human milk. Breast Cancer Res Treat 66: 1-7
[69] Schlange T, Schnipkoweit I, Andree B et al (2001). Chick CFC controls lefty 1 expression in the embryonic midline and nodal expression in the lateral plate. Develop Biol 234: 376-389
[70] Dono R, Scalera L, Pacifico F et al (1993). The murine CR-1 gene: Expression during mesoderm induction and early heart morphogenesis. Develop 118(4): 1157-1168
[71] Ding J, Yang L, Yan YT et al (1998). CR-1 is required for correct orientation of the anterior-posterior axis in the mouse embryo. Nature 395: 702-707
[72] Xu C, Liguori G, Persico MG et al (1999). Abrogation of the CR-1 gene in mouse leads to failure of postgastrulation morphogenesis and lack of differentiation of cardiomyocytes. Development 126(3): 483-494
[73] Shen M, Schier AF (2000). The EGF-CFC gene family in vertebrate development. TIG 16(7): 303-309
[74] Yeo CY, Whitman M (2001). Nodal Signals to Smads through Cripto-Dependent and Cripto-Independent Mechanisms Mol Cell 7: 949-957.
[75] Reissman E, Jörnvall H, Blokzijl A et al (2001). The orphan receptor ALK7 and the Activin receptor ALK4 mediate signaling by nodal proteins during vertebrate development. Genes Develop 15: 2010-2022.
[76] Gray PC, Harrison CA, Vale W. Cripto forms a complex with activin and type II activin receptors and can block activin signalling (2003). PNAS 100(9):5193-5198
[77] Cheng SK, Olale F, Bennett JT et al (2003). EGF-CFC proteins are essential coreceptors for the TGF-beta signals Vg1 and GBF1. Genes Dev 17(1):31-6
[78] Kenney NJ, Huang RP, Johnson GR et al (1995).Detection and location of amphiregulin and Cripto-1 Expression in the developing postnatal mouse mammary gland. Mol Reprod Dev 41: 277-286
[79] Bianco C, Adkins HB, Wechselberger C et al (2002). Cripto-1 activates nodal and ALK4-dependent and independent signaling pathways in mammary epithelial cells. Mol Cell Biol 22(8): 2586-2597
[80] Kannan S, De Santis M, Lohmeyer M et al (1997). CR-1 enhances the tyrosine phosphorylation of Shc and activates Mitogen-activated Protein Kinase (MAPK) in mammary epithelial cells. J of Biol Chem 272 (6): 3330-3335
[81] Bianco, C; Kannan S, de Santis M et al (1999). CR-1 indirectly stimulates the Tyrosine Phosphorylation of erbB-4 through a novel receptor. J Biol Chem Vol. 274 (13): 8624-8629
[82] Bianco C, Strizzi L, Rehman A et al. A nodal and ALK4-independent signalling pathway activated by Cripto-1 through Glypican-1 and c-src (2003).Cancer Res 63: 1192-1197
[83] Ebert, AD, Wechselberger C, Frank S et al (1999). CR-1 induces phosphatidolinositol-3 kinase-dependent phosphorylation of AKT and GSK-3beta in human cervikal Carcinoma cells. Cancer Res 59: 4502-4505
[84] Kuniyasu H, Yoshida K, Yokozaki H et al (1991). Expression of CR-1, a novel gene of the Epidermal Growth Factor Family, in Human Gastrointestinal Karzinomas. Jpn J Cancer Res 82: 969-973

[85] Saeki T, Stromberg K, Qui C-F et al (1992). Differential Immunohistochemical Detection of Amphiregulin and CR-1 in Human Normal Colon and Colorectal Tumors. Cancer Res 52: 3467-3473
[86] Qui C.-F., Liscia D.S., Normanno N et al (1994). Expression of transforming growth factor alpha, amphiregulin and CR-1 in human breast carcinomas. Br Journal Cancer 69: 903-910
[87] Friess H, Yamanaka Y, Büchler M et al (1994). CR-1, a member of the epidermal growth factor family, is over-expressed in human pancreatic cancer and chronic pancreatitis. Int J Cancer 56: 668-674
[88] Byrne R, Autzen P, Birch P et al (1998). The imunhistochemical detection of CR-1-1 in benign and malignant human bladder. J Pathol 185: 108-111
[89] Baldassare G, Bianco C, Tortora G et al.(1996). Transfection with a CR-1 Anti-sense plasmid suppresses endogenuous CR-1 Expression and inhibits transformation in a human embryonal carcinoma cell line. Int J Cancer 66:538-543
[90] Ciardiello A, Dono R, Kim N et al.(1991). Expression of CR-1, a novel gene of the epidermal growth fator family, leads to in vitro transformation of a normal mouse mammary epithelial cell line. Cancer Res 51:1051-1054
[91] Ertoy D, Ayhan A, Sarac E et al (2000). Clinicopathological implication of cripto expression in early stage invasive cervical carcinomas. Eur J Cancer 36: 1002-1007
[92] Prigent SA, Lemoine NR (1992): The type 1 (EGF-related) family of growth factors and their ligands. Progress in growth factor research 4: 1-24
[93] Todaro GJ, De Larco JE (1978). Growth factors produced by sarkoma virus-transformed cells. Cancer Res 38: 4147-4154
[94] Kudlow JE, Bjorge JD (1990). TGF alpha in normal physiology. Cancer Biol 1:293-302
[95] Yasui W, Zhong-Quiang J, Kuiyasu H et al (1992). Expression of transforming growth factor alpha in human tissues: Immunhistochemical study and Northern blot analysis. Virchows Archiv A Pathol Anat Histopath 421: 513-519
[96] Zhu L, Kim K, Domenico DR et al (1996): Adenocarcinoma of duodenum and ampulla vater: clinicopathology study and expression of p53, c-neu, TGF alpha, CEA and EMA. J Surg Oncol 61:100-105
[97] Hise MK, Jacobs SC, Papadimitriou JC et al (1996): Transforming growth factor alpha expression in human renal carcinoma. Urology 47: 29-33
[98] Pecur L, Kapitanovic S, Sonicki Z et al (1994). Prognostic Significance of transforming growth factor alpha in human lung carcinoma: an immunhistochemical study. Anticancer Research 14: 2839-2843
[99] Piyathilake CJ, Frost AR, Manne U et al (2002). Differential expression of growth factors in squamous cell carcinoma and precancerous lesions of the lung. Clin Cancer Res 8: 734-744
[100] Grandis JR, Melhem MF, Gooding WE et al (1998). Levels of TGF alpha and EGFR Protein in Head and neck squamous cell carcinoma and patient survival. J of the Nat Cancer Institut 90 (11): 824-832
[101] Konishi I, Ishikawa Y, Wang S et al (1994). Expression of transforming growth factor alpha in the normal cervix and in benign and malignant lesions of the uterine cervix. Br J Obstet Gynaecol 101: 325-329
[102] Xynos FP, Klos DJ, Hamilton PD et al (1992). Expression of transforming growth factor alpha mRNA in benign and malignant tissues from gynecologic patients with various proliferative conditions. Anticancer Res 12(4): 1115-1120
[103] Bauknecht T, Kohler M, Janz I et al (1989). The occurrence of epidermal growth factor receptors and the characterization of EGF-like factors in human ovarian, endometrial, cervical and breast cancer.EGF receptors and factors in gynecological carcinomas. J Cancer Res Clin Oncol 115 (2): 193-199
[104] Coussens L, Yang-Feng TL, Liao LC et al (1985). Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with Neu oncogene. Science 230:1132-1139
[105] Andrulis IL, Bull SB, Blackstein ME et al (1998). Neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto breast cancer study group. J Clin Oncol 16(4): 1340-1349
[106] De Potter, C, Beghin C, Makar AP et al (1990). The neu-oncogene protein as a predictive factor for haematogenuous metastases in breast cancer patients. Int J Cancer 45: 55-58
[107] Rilke F, Conalghi MI, CascinelleN et al (1991). Prognostic Significance of HER-2/neu Expression in Breast Cancer and its relationship to other prognostic factors. Int J Cancer 49(1): 44-49
[108] Werkmeister R, Brandt B, Joos U (1996). The erbB oncogenes as prognostic markers in oral squamous cell carcinomas. Am J Surgery 172(6): 681-683
[109] Tzahar E, Yarden Y (1998): The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stroma ligands. Biochim Biophys Acta 1377: M25-M37
[110] Hale RJ, Buckley CH, Fox H et al (1992). Prognostic value of c-erbB-2 expression in uterine cervical carcinoma. J Clin Pathol 45: 594-596

[111] Oka K, Nakano T, Arai T (1994).C-erbB-2 Oncoprotein Expression is associated with poor prognosis in squamous cell carcinoma of the cervix. Cancer 73(3): 668-671
[112] Kristensen GB, Holm R, Abeler VM et al (1996). Evaluation of the prognostic Significance of Cathepsin D, Epidermal Growth Factor Receptor, and c-erbB-2 in early cervical squamous cell carcinoma. Cancer 78(3): 433-440
[113] Benedet JL, Miller DM, Nickerson KG et al (1987). The results of cryosurgical treatment of cervical intraepithelial neoplasia at one, five and ten years. Am J Obstet Gynecol 157(2): 268-273
[114] Tsukamoto N (1985). Treatment of cervical intraepithelial neoplasia with the carbon dioxide laser. Gynecol Oncol 2(3):331-336
[115] Bloss JD (1993). The use of elektrosurgical techniques in the management of premalignant diseases of the vulva, vagina and cervix: an excisional rather than an ablative approach. Am J Obstet Gynecol 169(5): 1081-1085
[116] Sevin BU, Nadji M, Averette HE et al. (1992).Microinvasive carcinoma of the cervix. Cancer 70 (8): S.2121-2128
[117] Jones WB, Mercer GO, Lewis JL jr et al.(1993) Early invasive carcinoma of the cervix. Gynecol Oncol 51 (1) : 26-32
[118] Grigsby PW, Perez CA (1991): Radiotherapy alone for medically inoperable carcinoma of the cervix: stage IA and carcinoma in situ. Int J of Rad Oncol Biol Phys 21(2): 375-378
[119] Piver MS (1990): Invasive Cancer of the cervix in the 1990s. Sem surg Oncol 6 (6): 359-363
[120] Cunningham MJ, Dunton CJ, Corn B et al (1991). Extended-field radiation therapy in early-stage cervical carcinoma: survival and complications. Gynecol Oncol 43(1):51-54
[121] Perez CA, Grigsby PW, Nene SM et al (1992). Effect of tumour size on the prognosis of carcinoma of the the uterine cervix treated with irradiation alone. Cancer 69 (11):2796-2806
[122] Downey GO, Potish RA, Adcock LL et al (1989). Pretreatment surgical staging in cervical carcinoma: therapeutic efficacy of pelvic lymph node resection. Am J Obstet Gynecol 160 (5, Part 1): 1055-1061
[123] Vigliotti AP, Wen BC, Hussey DH et al (1992). Extended field irradiation for carcinoma of the uterine cervix with positive periaortic nodes. Intern J of Rad Oncol Biol Phys 23 (3):501-509
[124] Rotman M, Pajak TF, Choi K et al (1995). Prophylactic extended field irradiation of para-aortic lymph nodes in stage IIB and bulky IB and IIA cervical carcinomas:ten year treatment results of RTOG 79-20. J of Am Med Ass 274(5): 387-393
[125] Dembo AJ, Balogh JM (1990). Advances in Radiotherapy in the gynecologic malignancies. Sem in Surg Oncol 6(6):323-327
[126] Dunst J, Haensgen G (2001). Simultaneous radiochemotherapy in cervical cancer: recommendations for chemotherapy. Strahlenther Oncol 177(12):635-40
[127] Sardi J, Sananes C, Giaroli A et al (1990). Neoadjuvant chemotherapy in locally advanced carcinoma of the cervix uteri. Gynecol Oncol 38(3):486-493
[128] Interdiziplinäre kurzgefasste Leitlinien der Deutschen Krebsgesellschaft und der Gesellschaft für Gynäkologie und Geburtshilfe. http://www.ago-online.de/leitlinien/zervix.pdf
[129] Pivers MS, Khalil M, Emrich LJ (1989) Hydroxyurea plus pelvic irradiation versus placebo plus pelvic irradiation in nonsurgically staged stage IIIb cervical cancer. J of Surg Oncol 42 (2): S. 120-125
[130] Gullick WJ. Production of antisera to synthetic peptides. In: J.M. Walker (ed.), Methods in Molecular Biology, Vol 3, 341-354. Clifton, NJ Humana Press, Inc., 1988
[131] Sorvillo JM, Mc Cormack ES, Yanez L et al (1990). Preparation and characterisation of monoklonal antibodys specific for human transforming growth factor alpha. Oncogene 5: 377-386
[132] Brandt R, Normanno N, Gullick WJ et al. (1994) Identification and biological characterisation of an Epidermal Growth Factor –related protein: CR-1. J Biol Chem 269:17320-17328
[133] von de Vijver MJ, Peterse JL, Wolter MJ et al (1988), Neu-Protein Overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognosis value in stage II breast cancer. NEJM 319(19):1239-1245.
[134] Schneider A, Possover M, Kühne-Heid R et al. (1997) Vergleich von peri- und postoperativen Parametern bei laparoskopisch-vaginalem oder abdominalem Vorgehen zur Behandlung des Zervixkarzinoms Stadium I und II. Geburtshilfe und Frauenheilkunde 57: 31-36.
[135] Ober KG, Meinrenken H, Fauvet E et al (1964). Gynäkologische Operationen. In Allgemeine und Spezielle chirurgische Operationslehre. Springer Berlin-Göttingen-Heidelberg-New York. S. 136-249.
[136] Schneider A, Krause N, Kühne-Heid R et al (1996). Erhaltung der Fertilität bei frühem Zervixkarzinom: Trachelektomie mit laparoskopischer Lymphonodektomie. Zentralbl Gynäkol 118: 6-8

[137] Peters WA, Liu PY, Barrett RJ et al (2000). Concurrent chemotherapy and pelvic irradiation therapy compared with pelvic irradiation therapy alone as adjuvant therapy after radical surgery in high-risk early stage cancer of the Zervix. J Clin Onc 18:1606-1613
[138] Morris M, Eifel PJ, Lu J (1999). Pelvic irradiation with concurrent chemotherapy compared with pelvic, para-aortic radiation for high-risk cervical cancer. N Engl J Med 340:1137-1143
[139] Rose PG, Bundy BN, Watkins EB (1999). Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Eng J Med 340:1144-1153
[140] Keys HM, Bundy BN, Stehman FB (1999) Cisplatin, radiation and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Eng J Med 340: 1154-1161
[141] Kim RY, Alvarez RD, Omura GA (2002). Advances in the treatment of gynecologic malignancies. Part 1: cancers of cervix and vulva. Oncol (Huntington) 16(11): 1510-1517
[142] Thigpen T, Vance Rb, Khansur T (1994): Carcinoma of the Uterine Zervix: Current Status an Future Directions. Sem Oncol 21(2, Suppl 2): 43-54
[143] Thomas GM, Dembo AJ, Black B et al (1987). Concurrent radiation and chemotherapy for carcinoma of the cervix recurrent after radical surgery. Gynecol Oncol 27(3): 254-260.
[144] Rosa FM (2002). Cripto, a multifunctional partner in signaling: molecular forms and activities. Science STKE 158:PE47
[145] Pfeiffer D, Spranger J, Al-Deiri M et al (1997). mRNA Expression of Ligands of the Epidermal Growth Factor Receptor in the Uterus; Int. J. Cancer 72, 581-586
[146] Ferenczy A, Jenson AB (1996): Tissue effects and host response-the key to the rational triage of cervical neoplasia. Obstetrics and gynecological clinics of North America 23:759-782
[147] Doorbar J, Ely S, Sterling J et al (1991). Specific Interaction between HPV 16 E 1-4 and cytokeratins results in collapse of the epithelial cell intermediate filament network. Nature 352: 824-827
[148] Leechanachai P, Banks L, Moreau F et al (1992).The E 5 Gene from human papillomavirus type 16 is an oncogene which enhances growth factor-mediated signal transduction to the nucleus. Oncogene 7: 19-25
[149] Xiong Y, Kupuswamy D, Li Y et al (1996). Alteration of cell cycle kinase complexes in human papillomavirus E 6 and E 7 expressing fibroblasts precedes neoplastic transformation. J Virol 70: 999-1008
[150] Stillman B (1994). Smart machines at the DNA relication fork. Cell 78:725-728
[151] Hickman ES, Picksley SM, Vousdon KH (1994). Cells expressing HPV 16 E 7 continue cell cycle progression following DNA damage induced p53 activation. Oncogene 9:2177-2181
[152] Klingelhutz AJ, Foster SA, Mc Dougall JK (1996). Telomerase activation by the E6 gene product of human papillovirus type 16. Nature 380: 79-82
[153] Antinore JL, Birrer MJ, Patel D et al (1996). The human papillomavirus type 16 E 7 Gene product interacts with and trans-activates the AP 1 family of transcription factors. EMBO J 15:1950-1960, (1996)
[154] Lee DK, Kim BC, Kim IY et al (2002). The human papilloma virus E7 oncoprotein inhibits transforming growth factor-beta signalling by blocking binding of the Smad complex to its target sequence. J Biol Chem 277(41):38557-64
[155] Chen YG, Lui HM, Lin SH (2002). Regulation of Cell Proliferation, Apoptosis, and Carcinogenesis by Activin. Exp Biol Med 227(2):75-87
[156] Hempen PM, Zhang L, Bansal RK et al (2003). Evidence of Selection for clones having genetic inactivation of the Activin A type II Receptor (ACVR2) gene in gastrointestinal cancer. Cancer Res 63: 994-999
[157] Petraglia F, Florio P, Luisi S et al (1998). Expression and Secretion of Inhibin and Activin in normal and neoplastic uterine tissues. High levels of serum Activin A in women with endometrial and cervical carcinoma. J of Clin Endocrin Met 83(4):1194-1200
[158] Ebert AD. Expression von Cripto-1 (CR-1) einem Liganden der EGF-verwandten Wachstumsfaktorsuperfamilie, in menschlichen Zervixkarzinomen in vitro und in vivo. Habilitationsschrift. Berlin 1999
[159] Chang, JL, Tsao YP, Liu DW et al (1999). The Expression of Type 1 Growth Factor Receptors in the Squamous Neoplastic Changes of the Uterine Cervix. Gynecol Oncol 73, 62-71
[160] Turek, LP, Smith EM (1996). The genetic programm of genital human papillomaviruses in infection and cancer. Obstetrics and Gynecology clinics of North America 23:735-758
[161] Chang TL, Tsao YP, Liu DW et al (2001). The expression of HPV-16 E5 protein in squamous neoplastic changes in the uterine cervix. J Biomed Sci 8(2):206-13
[162] Kannan S., De Santis M., Lohmeyer M et al (1997). CR-1 enhances the tyrosine Phosphorylation of Shc and activates mitogen-activated protein kinase (MAPK) in mammary epithelial cells.J Biol. Chem., 272:3330-3335
[163] Wechselberger C, Ebert AD, Bianco C et al (2001). CR-1 Enhances Migration and Branching Morphogenesis of Mouse Mammary Epithelial Cells. Experimental Cell Research 266, 95-105
[164] Takeichi M (1991): Cadherin cell adhesion receptors as morphogenic regulator. Science 251: 1451-1455

[165] Frame MC (2002). Src in cancer:deregulation and consequences for cell behaviour. Biochim Biophys Acta 1602: 114-130
[166] Ebert AD., Wechselberger C, Nees M et al (2000). CR-1 induced increase in vimentin expression is associated with enhanced migration of human Caski cervikal Carcinoma cells. Exp Cell Res 257:223-229.
[167] Gilles C, Polette M, Piette J et al. (1996) Vimentin Expression in cervical carcinomas: Association with invasive and migratory potential. J of Pathology 180: 175-180
[168] Dublin EA, Bobrow LG, Barnes DM (1995). Amphiregulin and cripto overexpression in breast cancer: relationship with prognosis and clinical and molecular variables. Int J Onc 7: 617-622
[169] Panico L, D'Antonio A, Salvatore G (1996). Differential immunhistochemical detection of transforming growth factor alpha, amphiregulin and cripto in normal and malignant breast tissues. Int J Cancer 65:51-56
[170] Kohler M.; Janz I; Wintzer HO et al (1989). The expression of EGF receptors, EGF-like factors and c-myc in ovarian and cervical carcinomas and their potential clinical significance. Anticancer Research 9:1537-1548
[171] van Dam P A; Lowe D G; Watson J V et al (1991). Multiparameter flow-cytometric quantitation of epidermal growth factor receptor and c-erbB-2 oncoprotein in normal and neoplastic tissues of the femal genital tract. Gynecol Oncol 42:256-264
[172] Hale RJ; Buckley CH; Gullick WJ et al (1993). Prognostic value of epidermal growth factor receptor expression in cervical Karzinoma. J Clin Path 46:149-153
[173] Pillai MR, Jayaprakash PG, Nair MK (1998). Tumour-proliferaive fraction and growth factor expression as markers of tumour response to radiotherapy in cancer of the uterine cervix. J Cancer Res Clin Oncol 124:456-461
[174] Yan, Y; Nakagawa H, Lee M et al (1997). Transforming Growth Factor alpha enhances cyclin D1 transcription through the binding of early growth response proetein to a cis-regulatory element in the cyclin D 1 promoter. J of Biol Chem 272:33181-33190
[175] Löffler G; Petrides P E. Biochemie und Pathobiochemie. 5. Auflage Berlin 1997: S.1092, 1097-1099
[176] Tungekar M F, Linehan J (1998). Patterns of expression of transforming growth factor and epidermal growth factor receptor in squamous cell lesions of the urinary bladder. J Clin Path 51: 583-587 (1998)
[177] Wang D, Li W, Jiang W et al (1998). Autocrine TGF alpha expression in the Regulation of initiation of human colon carcinoma growth. J of Cellular Physiology 177: 387-395
[178] De Long J S, van Diest P J, van der Valk P. et al.(1998). Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer.I: An inventory in search of autocrine and paracrine loops. J of Pathology 184: 44-52
[179] Gazzaniga P, Gradilone A, Silvetsri I et al (1998). High Levels of Transforming Growth Factor alpha (TGF alpha) mRNA may predict local relapses in early stage urinary bladder cancer. Eur J of Cancer 34: 934-936
[180] Türkeri LN, Erton ML, Cevik I et al (1998). Impact of the expression of epidermal growth factor, transforming growth factor alpha, and epidermal growth factor receptor on the prognosis of superficial bladder cancer. Urology 51:645-649
[181] Straight SW, Hinkle PM, Jewers RJ et al (1993). The E5 oncoprotein of human papillomavirus type 16 transforms fibroblasts and effects the downregulation of the Epidermal Growth Factor Receptor in Keratinocytes. J of Virology 67: 4521-4532
[182] De Bortoli M, Dati C, Antoniotti S et al (1992).Hormonal regulation of c-erbB-2 oncogene expression in breast cancer cells. J Steroid Biochem Mol Biol 43 (1-3): 21-5
[183] Kim JW, Sung HR, Kim DK et al (1992). Estrogen and progesteron receptor assay in carcinoma of the cervix with monoclonal antibodies. Gynecol Oncol 47(3): 306-10
[184] Hunter RE, Longcope C, Knough P (1987). Steroid hormone receptors in carcinoma of the cervix. Cancer 60(3):392-6
[185] Nonogakin U, Fujii S, Konishi I et al (1990). Estrogen receptor localization in normal and neoplastic epithelium of the uterine cervix. Cancer 66(12):2620-7
[186] Kanai M, Shiozawa T, Xin L et al (1998). Immunhistochemical detection of the sex steroid receptors, cyclins, and cyclin dependant kinases inj the normal and neoplastic squamous epithelia of the uterine cervix. Cancer 82(9): 1709-19
[187] Gompel A, Martin A, Simon P et al (1996). Epidermal growth factor receptor and c-erbB-2 expression in normal breast tissue during the menstrual cycle. Breast cancer Res Treat 38(2):227-35
[188] Yoshida S, Maruo T, Matsuo H (1995). Effects of estrogen and thyroid hormone on EGF-Receptor expression, proliferative activity and SCC production in the CasKi cervical carcinoma cells . Nippon Sanka Fujinka Gakkai Zasshi. 47(2) 149-55. Abstract englisch, Originalartikel Japanisch.
[189] Golijow CD, Abba M, Mouron SA et al (2001). Detection of c-erbB-2 gene amplifikation in cervical scrapes positive for human papillomavirus (HPV). Cancer Invest 19(7):678-83

[190] Mouron S, Martin CA, Güerci A et al (2000). Association between activated k-ras and c-erbB-2 oncogenes with "high-risk" and "low-risk" Human Papillomavirus types in preinvasive cervical lesions. Mutation Res 468: 127-134
[191] Pauletti G, Godlphin W, Press MF et al (1996). Detection and quantification of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridisation. Oncogene 13: 63-72
[192] Hynes NE, Stern DF (1994). The biology of erbB-2/neu/HER-2 and ist role in cancer (1994). Biochem Biophys Acta Rev Cancer 1198:165-184
[193] al Kasspooles M, Moore JH, Orringer MB et al (1993). Amplification and overexpression of the EGFR and ErbB-2 gene in human esophageal adenocarcinoma (1993). Int J Cancer 54(2) 213-9
[194] Nakamura H, Saji H, Ogata A et al (2003). Correlastion between encoded protein overexpression and copy number of the HER-2 Gene with survival in non small cell lung cancer .Int J Cancer 103(1):61-66
[195] Morali F, Cattabene M, Tagliabue E et al (1993). Overexpression of p 185 is not related to erbB2 amplification in ovarian cancer. Ann Oncol 4: 775-779
[196] Hollywood DP, Hurst HC (1993). A novel transcription factor, OB2-1, is required for overexpression of the proto-oncogene c-erbB-2 in mammary tumour lines. EMBO 12(6): 2369-2375
[197] Taylor SL, Platt Higgins A, Rudland PS et al. (1998). Cytoplasmatic staining of erbB-2 is not associated with the presence of detectable c-erbB-2 mRNA in breast cancer specimens. Int J Cancer 76: 459-463
[198] Venter DJ, Tuzi NL, Kumar S et al (1987). Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunhistochemical assessment correlates with gene amplification . Lancet 2, 69-72
[199] Birner P, Oberhuber G, Stani J et al (2001). Evaluation of the United States Food and Drug Administration-approved Scoring and Test System of HER-2 Protein Expression in Breast Cancer. Clin Cancer Res 7:1669-1675
[200] Gebhard F, Zänker KS, Brandt B (1998). Differential Expression of alternatively spliced c-erbB-2 mRNA in Primary tumours, Lymph node Metastases, and Bone Marrow Micrometastases from Breast cancer Patients. Biochem Biophys Res Comm 247, 319-323 .
[201] Aigner A, Juhl H, Malerczyk C et al (2001). Expression of a truncated 100 kD HER2 Splice Variant acts as an endogenous inhibitor of tumour cell proliferation. Oncogene 20 (17): 2101-2111
[202] De Potter CR, Quatacker J, Maertens G et al (1989). The subcellular localization of the neu protein in human normal and neoplastic cells. Int J Cancer 44: 969-974
[203] Coombs LM, Oliver S, Sweeney E et al. Immuncytochemical localisation of c-erbB-2 protein in transitional dell carcinoma of the urinary bladder (1993). J of Pathol 169: 35-42
[204] Coombs LM, Pigott DA, Sweeney E et al. Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder (1991). Br J Cancer 63: 601-608
[205] Akiyama T, Sudo C, Ogawara H et al (1986). The product of the human c-erbB-2 gene: a 185 kilodalton protein with tyrosine kinase activity. Science 232, 1644-46
[206] Kapitanovic S, Radosevic S, Kapitanovic M et al (1997). The expression of p185HER-2/neu correleates with the stage of disease and survival in colorectal cancer. Gastroenterology 112:1103-1113
[207] Xie Y, Hung MC (1994). Nuclear translocalization of p185neu tyrosine kinase and its association with transkriptional transactivation. Biochem Biophys Res Comm 203:1589-1598
[208] Lin SY, Makino K, Xia W et al (2001). Nuclear lokalization of EGF receptor and its potential new role as a transcription factor (2001). Nat Cell Biol 3(9): 802-8
[209] Sarup JC, Johnson RM, King KL et al.(1991). Characterisation of an anti-p185HER2 monoclonal antibody that stimulates receptor functions and inhibits tumour cell growth. Growth Regulation 1:72-82
[210] Hurwitz E, Stancovski I, Sela M, Yarden Y (1995). Suppression and promotion of tumour growth by monoclonal antibodies to the erbB-2 differentially correlate with cellular uptake. Proc Natl Acad Sci 92:3353-3357
[211] Karunagaran D., Tzahar E. Beerli Ret al (1996). ErbB-2 is a comon auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 15:254-264
[212] Alroy I, Yarden Y (1997). The erbB signalling network in embryogenesis and oncogenesis: Signal diversification through combinatorial ligand-receptor interactions. FEBS lett 410:83-6
[213]Ben-Levy R, Paterson H.F, Marshall C.J et al (1994). A single autophosphorylation site confers oncogenicity to the neu/erbB-2 receptor and enables coupling to the MAP Kinase pathway EMBO J 13:3302-3311
[214] Ye J, Xu, RH, Taylor-Papadimitriou J et al (1996). Sp1 binding plays a critical role in erbB-2 and v-ras-mediated downregulation of alpha 2 Integrin expression in human mammary epithelial cells. Molecular and cellular biology 16: 6178-6189

[215] Kanai Y, Ochiai A, Shibata T et al (1995). C-erbB-2 gene product directly associates with beta catenin and plakoglobin. Biochemical and biophysikal research communications 208:1067-1072
[216] Mitra AB, Murty VVVS,Mahendra P et al.(1994). ErbB2 (HER2/neu) Oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix. Cancer Res 54: 637-639
[217] Berchuck A., Rodriguez G, Kamel A(1990). Expression of Epidermal Growth Factor Receptor and HER-2/neu in Normal and Neoplastic Zervix, Vulva and Vagina. Obstetrics and Gynecology 76:381-387
[218] Tervahauta A, Syrjänen S, Syrjänen K (1994). Epidermal Growth Factor Receptor, c-erbB-2 Proto-Oncogene and Estrogen Receptor Expression in human Papillovirus Lesions of the Uterine Zervix. Int J Gynecol Pathol 13:234-240
[219] Brumm C, Rivière A, Wilckens C et al (1990). Immunhistochemical detection and Northern Blot analysis of c-erbB-2 expression in normal, premalignant and malignant tissues of the corpus and Zervix uteri. Virchows Archiv A Pathol Anat 417:477-484
[220] Mandai M, Konishi I, Koshiyama M et al (1995). Altered expression of nm23-H1 and c-erbB-2 proteins have prognostic significance in adenocarcinoma but not in squamous cell carcinoma of the uterine cervix. Cancer 75(10):2523-2529
[221] Ngan JL, Cheung AN, Liu SS et al (2001). Abnormal expression of epidermal growth factor receptor and c-erbB-2 in squamous cell carcinoma of the cervix. Correlation with human papillomavirus and prognosis. Tumour Biol 22(3):175-83
[222] Kokai Y, Myers JN, Wada T et al. (1989). Synergic interaction of p185c-neu and the EGF-Receptor leads to transformation of rodent fibroblasts. Cell 58: 287-292
[223] Baulida J, Kraus MH, Alimandi M et al (1996). All ErbB Receptors Other Than the Epidermal Growth Factor Receptor are endocytosis impaired . J of Biol Chem 271(9):5251-5257
[224] Waterman H, Sabanais I, Geiger B et al (1998). Alternative Intracellular Routing of ErbB Receptors may determine their signaling potency. J of Biol Chem 273(22): 13819-13827